Frontlight ResearchEarly access
TerminatedPhase 3
Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy
Key facts
- Who runs it
- Amryt Pharma
- Where
- Belgium, France, Germany, and Italy12 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 1 person enrolled
- Started
- 23 May 2025
- Ended
- 11 Feb 2026
- Type of study
- Interventional
- Treatments tested
- Metreleptin
- Record updated
- 22 July 2026
- Why it stopped
- This clinical trial was closed early due to no longer being a requirement to the European Medicines Agency.
Who can take part
- Age
- Up to 5 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Confirmed diagnosis of Generalised Lipodystrophy
- Metreleptin treatment naive
Who cannot take part
- Weight <9 kg at Screening (Visit 1)
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia
The group in the trial
- MetreleptinTreatment being tested
Metreleptin \[Recombinant-methionyl human Leptin; rmetHuLeptin\] for daily injection is a sterile, white, solid lyophilised cake
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Open-label, Phase 3b Study to Evaluate Effectiveness, Safety and Pharmacokinetic Parameters of Metreleptin in Patients Under 6 Years of Age With Generalised Lipodystrophy and Associated Diabetes Mellitus and/or Hypertriglyceridaemia
- Record updated
- 22 July 2026